Skip to content

A randomized, double-blind, cross-over clinical trial of Sinisan in improving depression state of breast cancer patients with mild to moderate depression

A randomized, double-blind, cross-over clinical trial of Sinisan in improving depression state of breast cancer patients with mild to moderate depression

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006710
Enrollment
Unknown
Registered
2022-10-25
Start date
2022-10-31
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild to moderate depression of Breast cancer patients

Interventions

A:Sinisan-Washout period-Placebo
B:Placebo-Washout period-Sinisan

Sponsors

Zhiyu Wang
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Pathologically diagnosed breast cancer patient, in line with clinical diagnosis of breast cancer; (2) 18 years to 75 years old; (3) Combined with PHQ -9 and Hamd -24, the patients were diagnosed as mild to moderate depression by psychologists; (4) Theoretically Diagnosed stagnation of liver-qi syndrome of Traditional Chinese medicine; (5) ECOG=2; (6) Be able to understand the questions in the scale and complete it; (7) Volunteer to participate in the clinical study and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Patients with history of other malignant tumors; (3) Patients with diagnosed major depressive disorder; (4) Patients with cardiovascular diseases , liver and kidney dysfunction and other serious diseases; (5) Previous diagnosis of mental disorder or Bipolar Disorder; alcohol and drug abusing history; (6) patients who used antidepressant, antipsychotics or accept any form of psychological treatment within 2 weeks before treatment; (7) patients who were participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Depression scores as assessed by HAMD-24;

Secondary

MeasureTime frame
Depression scores as assessed by PHQ-9;Depression scores as assessed by TCM symptom rating scale;Quality of life scores as assessed by FACT-B;Cholic acid metabolism in peripheral blood;T lymphocyte subsets in peripheral blood;

Countries

China

Contacts

Public ContactZhiyu Wang
wangzhiy976@126.com+86 18819480766

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026